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Summary.-The reactivity of lymphocytes from patients with either carcinoma of
the breast orlarge bowel has been studied using thehumanto mouse normal lympho-
cyte transfer (NLT) reaction. It was found that, in the case of breast cancer, there
was a direct correlation between the clinical stage and a reduced NLT reaction.
Only patients with regional lymph node or generalized metastases showed signifi-
cantly reduced lymphocyte reactivity. However, in the case of large bowel cancer
there was a generalized reduction in NLT reactivity which was independent of the
clinical stage. Incubation of lymphocytes from individuals without neoplastic
disease in serum or plasma from breast cancer patients, showing reduced NLT
reactivity, resulted in a reduced NLT reaction. This appears to be indicative of
the presence of circulating " blocking factor " in such patients.
HUGHES and Mackay (1965) demon-
strated a decrease in skin reactivity to
tuberculin, in patients with carcinoma
of the breast, in whom the disease was
no longer localized. Roberts (1974) skin
tested breast cancer patients with the
antigen Varidase which is a mixture
of streptokinase and streptodornase. It
was found that reactivity was reduced
even in patients with localized disease.
This finding was supported by investiga-
tions oil lymphocyte reactivity in vitro.
Whittaker and Clark (1971) and Watkins
(1973) demonstrated diminished lympho-
cyte responsiveness to phytohaemagglu-
tinin in early breast cancer patients.
However, whilst the stage at which
immunodepression was first manifest is
disputed, all authors agree that it is
progressive with advancing disease.
A similar situation obtains in carci-
noma of the rectum where the skin
reactivity of patients to the antigen
2,4-dinitrochlorobenzene is reduced in
direct proportion to the clinical stage
of the disease (Bone and Camplejohn,
1973). It thus seemed of interest to
evaluate further the lymphocyte reacti-
vity, in vivo, of patients with these types
of malignant neoplasia. To this end the
human to mouse normal lymphocyte
transfer (NLT) reaction (Rees and Symes,
1973) has been employed.
MATERIALS AND METHODS
Clinical material
A total of 38 patients with carcinoma
of the breast and 18 with carcinoma of the
large bowel have been studied. All cases
were staged according to the TNM classifica-
tion (Bailey and Love, 1971; Wood, 1971).
In addition, as control material, 15 patients
with benign breast neoplasms and 17 post-
surgical cases with non-neoplastic conditions
were investigated. The above figures apply
to patients from each of whom 10 million
lymphocytes were transferred to a mouse.
The NLT reactivity offurther smaller groups
of patients was studied at the 5 million cell
level.
* Present address: Department of Surgery, Banting Institute, 100 College Street, Toronto, Ontario,
Canada.LYMPHOCYTE REACTIVITY IN CARCINOMA OF BREAST AND LARGE BOWEL
Normal lymphocyte transfer reaction
On Day 0 lymphocytes were injected
intradermally into the shaved flank of an
outbred Ash Porton mouse. One such injec-
tion of 5 or 10 million cells in 0-1 ml was
made for eack patient, except in cases where
the number of cells obtained allowed simul-
taneous testing at the 5 and 10 million cell
level. The diameter of the NLT reaction
in mm was measured on Day 2 using a
caliper with a vernier scale. Two readings
(to the nearest 0 5 mm) were taken at right
angles and the result expressed as a mean.
All lesions were measured by two independent
observers. The lesion was sharply demarcat-
ed against the shaved skin of the mouse
in the majoritv of cases. However, where
the lesion was ill-defined, the area of the
skin bearing the reaction was excised. The
deep aspect of the reaction, which was
invariably clearly seen, was then measured.
To determine the reproducibility of the
reaction for lymphocytes from a single
individual 19 tests at a 10 x 106 lymphocyte
level were made for a single healthy male.
This gave a mean reaction size of3-15 -± 0-45
(s.d.) mm which was suitably consistent.
Separation of lymphocytes from venous
blood
In patients undergoing excision biopsy
of a breast lump or mastectomy, 20 ml
heparinized venous blood were obtained
prior to the commencement of surgery.
A similar sample of blood was also obtained
from each patient with carcinoma of the
large bowel, prior to surgery. Lymphocytes
were separated by density gradient centri-
fugation after the blood had been layered
on to a Ficoll-Isopaque column (Rees and
Symes, 1973). Alternatively the blood was
layered onto a Ficoll (9%, 24 parts) Triosil
(34%, 10 parts) column. Equal volumes of
Ficoll-Triosil and blood were then centrifuged
at 2000 g for 20 min after which the lympho-
cytes were separated and washed as pre-
viously described (Rees and Symes, 1973).
Studies on the effect of incubation, with
plasma or serum from patients with meta-
static breast cancer, on the reactivity of
lymphocytes from healthy individuals
In order to determine whether a lympho-
cyte blocking factor was present in patients
with advanced breast cancer, plasma and
serum from these individuals was incubated
with lymphocytes from individuals free of
neoplastic disease. The lymphocytes were
obtained from the peripheral blood of a
single healthy individual or from the spleens
of patients undergoing splenectomy for
benign oesophageal stricture.
In the case of a spleen, a nucleated cell
suspension, in medium 199, was prepared by
gently pressing and washing spleein slices
through stainless steel sieves of decreasing
porosity, 40, 100 and finally 200 mesh.
The concentration of the suspension was
adjusted to approximately 30 million cells
per ml, and this was layered onto a Ficoll-
Isopaque or Ficoll-Triosil mixture, as for
venous blood.
In each experiment aliquots from the
same lymphocyte suspension were incubated
in some of the following: medium 199,
plasma or serum from individuals without
neoplasia, and plasma or serum from patients
with metastatic breast cancer. All plasma
or serum samples were heated to 56°C
for half an hour prior to use. Each plasma
or serum sample was diluted to one-fifth
in 199 and incubated for 45 min at 370C.
Following incubation the lymphocytes were
washed once in 199. Using each aliquot
oflymphocytes, multiple NLT reactions were
then performed.
Statistical treatment of the data
In a number of cases the reaction follow-
ing lymphocyte transfer was recorded as
" Nil ". Hence, in order to calculate the
degree of significance between the NLT
reactivity of cancer patients and controls,
the non-parametric Rank-Sum Test (two
populations), Hayslett (1968), was employed.
In addition, the means and standard devia-
tions ofthe reactions which could be measured
were recorded.
The data on reactivity of lymphocytes
following incubation in plasma did not
contain any " Nil " readings, so the usual
paranmetric tests for significance were em-
ployed. However, " Nil " readings were
present following incubation in serum, so
again the Rank-Sum Test was used.
RESIULTS
The lymphocyte reactivities of the
several categories of individuals with
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TABLE I.-The Immunocompetence, as Assessed by the Human to Mouse Normal
Lymphocyte Transfer Reaction, in Patients with Breast and Colon Carcinoma. In
Each Case 10 Million Lymphocytes were injected I.D. and the Reaction Read on
Day Two
Rank-Sum test
Category
A. Surgical patients with non-
malignant conditions
B. Patients with benign breast
neoplasms
Patients with Ca breast
C. T No
D. T2-3No
E. T2-3N2
F. Multiple metastases
G. Ca colon or rectum
NLT reaction
No* Mean diam. (mm) ±s.d.
17 2-85+1-09
15 2-73±0-93
11 2-13±0-94
10 2-71±0-93
7 1-91±1-09
2 1-15
12 2-42±0-55
Versus
t
_
No* A
19
15
11 Z-1-07NS
11 NS
10 Z-2-41
P<0.01
<0-002
6 Z-2-93
P<0-01
>0-002
18 Z-2-07
P<0-02
>001
* The difference between these two numbers equals the number of nil reactions.
and without neoplastic disease are pre-
sented in Table I. It may be seen that
patients with breast cancer but without
nodal metastases (categories C and D)
showed no reduction in NLT reactivity
when compared with either post-surgical
cases with non-neoplastic conditions (cate-
gory A), or patients with benigni breast
neoplasms (category B). This was true,
irrespective of the size of the primary
cancer, which was less than 2 cm diameter
in category C and from 2-10 cm in
category D. However, the occurrence
of lymph node metastases (category E)
led to a significant reduction in lympho-
cyte reactivity.
An even greater reduction in NLT
reactivity was seen in breast cancer
patients with multiple metastases (cate-
gory F). In addition the NLT reactivity
at the 5 million cell level, was compared
between patients in categories B and F.
The individual reaction sizes were: Cate-
gory B, 1-3 : 2-5 2-5: 2-8: 2-8 mm.
Category F, Nil : Nil: Nil: Nil: Nil : 0-5
mm. Using the Rank-Sum Test R - 45,
B > F, P < 0-04.
Lymphocyte reactivity was reduced
in a proportion of the patients with
large bowel cancer. However, this reduc-
tion showed no correlation with TNM
stage, Table II. If the NLT reactivity
TABLE II.-A Synopsis of Patients with
Carcinoma of the Colon or Rectum, in
which Immunocompetence was Assessed
by the Human to Mouse Normal Lympho-
cyte Transfer Reaction
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Age
77
72
78
80
74
68
64
64
82
60
69
64
71
84
77
65
65
70
72
Sex
9
Is
Is
6'
Stage
T,NoMo
T3NoMo
T3NoMo
T3NoMo
T3NoMo
T3NoM,
T3NoM2
T3N1Mo
T,N1Mo
T3N1Mo
T3N1Mo
T3N,M1
T3N M1
T3NlM2
T3N2M1
T3N2M2
T3N2M2
T3N2M2
T4NlMo
NLT reaction (mm)
5x 106 10 x 106
Nil
2-0
1-8
Nil
3-0 2-5
Nil 2-8
Nil
Nil
Nil
3-0
Nil
1-5
2-8
2-8 3-0
1-8
Nil
2-0
Nil
Nil
B
Z-1-37NS
NS
Z-2-58
P<0.01
<0-002
Z-3-19
P<0- 002
>0-001
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of these cases as a whole, category G,
is compared with that of patients in
category A, Table I, then a significant
reduction for the cancer p)atients is
seen.
The effect of incubating lymphocytes
from individuals without neoplasia in
plasma of patients with metastatic car-
cinoma of the breast is shown in Table
III. Plasma from two of three patients,
B and C, significantly inhibited lympho-
cyte reactivity. The results of similar
experiments involving serum rather than
plasma are presented in Table IV. Again,
sera from four different patients with
metastatic breast carcinoma each signifi-
cantly reduced lymphocyte reactivity in
comparison with serum from individuals
without neoplasia.
DISCUSSION
In the present experiments, the reac-
tivity of patients' lymphocytes is mea-
sured in vivo against a non-tumour-
specific antigen mouse, which they had
not previously encountered. Thus, a
problem of interpretation which arises
with in vivo immunocompetence testing
using tuberculin or Varidase, is avoided.
The results reported in the case of
breast cancer patients support the hypo-
thesis that diminished lymphocyte reac-
tivity follows the onset of malignant
neoplasia. Thus, they are against the
concept that carcinoma of the breast
arises from a defect in immune sur-
veillance.
The idea that depression of lympho-
cyte function is due to the presence
of a tumour invites a consideration of
mechanisms. The finding that NLT reac-
tivity was reduced following incubation
of lymphocytes from individuals without
neoplasia in the presence of plasma or
serum from cases of metastatic breast
carcinoma suggests the involvement of
a circulating factor. Similar diminution
of lymphocyte responsiveness to PHA
TABLE III. The Effect on NLT Reactivity ofIncubatingt Peripheral Blood Lymphocytes
or Splenic Lymphocytes with Plasma from Patients with Metastatic Breast Cancer
Type of
lymphocyte
PBL Ex. 1
Ex. 2
Splenic Ex. 1
Ex. 2
Ex. 3
Incubation
Healthy
In medium 199 $ plasma
2-5 (3)**±0-16 2-6 (3)±0 16
3-9 (9)10 24
2-7 (6)±-0-23
2 4 (6)±0 23 2 - 0 (6) ±0 23
2-8 (3)10-16
Patient's plasma
A B C
2.8 (4) 0-13 2-1 (4)tt+0-13
2-8 (7)tt±036
2 - 4 (6)±0- 19
1-5 (6)10 23 2-2 (6)10 23
2 7 (3) +0 - 16 2 0 (3)tt± 0 - 16
t Plasma dilution 1/5 45 min at 37°C.
** Mean diameter of NLT (mm) and ( ) number of observations ± S.E.
Significantly reduced P < 0 02tt P < 0-05t. Calculated by an analysis of variance on the
total data for the experiments PBL Ex. I and splenic Ex. 2 and 3 by Student's t test for PBL Ex. 2 and
splenic Ex. 1.
TABLE IV. The Effect on NLT Reactivity of Incubating Peripheral Blood or Splenic
Lymphocytes with Serum from Patients with Metastatic Breast Cancer
Type and
number of
lymphocytes
7 x 106 PBL
15 Y 106 Splenic
Incubation
Healthy serum
Patient I
Patient 2
Medium 199
Healthy serum
Patienit 3
Patient 4
NLT reactions
(individual values)
2-8 :3 0:3 0:3 : 3-8
00 :00 :00 : 2-3: 3-3
00 00 : 1-0: 2-5: 2-5
2-3 :2-3 :2-3 : 2-8 :2 8
2-0 :2-3 :2-3 :2-8 :2-8 :2-8
00 0:0 0:0 0:0 :0 5:0 5
00 0:0 0:0 0:0 :0 5: 1-0
Rank-Sum test
versus incubation
in normal serum
R=18-5 P<0 05
R=15-0 P<0*03
R=24 NS
R=21 P<0*02
R=21 P<0 02
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iii the presence of cancer patients' plasma
was reported by Silk (1967). Gatti et
al. (1970), Whittaker and Clark (1971)
and Suciu-Foca et al. (1973), reported
analogous findings following incubation
of normal lymphocytes and sera from
patients with solid tumours.
The nature of this circulating blocking
factor is not known. However, Baldwin
et al. (1973) incubated lymphocytes from
rats immune to hepatoma, with a hepa-
toma-specific antigen extracted from this
tumour. This resulted in abrogation of
the cytotoxicity of the immune lympho-
cytes for the tumour. It is thus possible
that the presence of circulating tumour
antigen may explain the blocking of
lymphocyte reactivity reported above.
This hypothesis is being investigated by
incubating normal lymphocytes with the
high and low molecular weight fractions
obtained following gel filtration on Sepha-
dex G-150, of sera from breast cancer
patients. The implication oftumour anti-
gen would of course imply its ability
to depress non-specific lymphocyte reac-
tivity, as opposed responsiveness to tu-
mour antigen. This has not, so far,
been demonstrated, but the possibility
seems worthy of investigation.
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